Research graph
References from Biosimilars in diabetic macular edema: Promise, progress, and pitfalls. Local targets link to admitted publications; unresolved targets remain external evidence.
Global prevalence of diabetic retinopathy and projection of burden through 2045
10.1016/j.ophtha.2021.04.027 · 2021 · External reference
An overview on Anti-Vegf and in search for an ideal anti VEGF agent
2022 · External reference
Anti-VEGF for the management of diabetic macular edema
10.1155/2014/632307 · 2014 · External reference
Real-world injection frequency and cost of ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration and diabetic macular edema
2020 · External reference
Future of anti-VEGF: Biosimilars and biobetters
10.1186/s40942-021-00343-3 · 2022 · External reference
A regulatory perspective on biosimilar medicines
10.3390/pharmaceutics16030321 · 2024 · External reference
Biosimilars in the treatment of retinal disease in the United States
10.3928/23258160-20230508-01 · 2023 · External reference
Biosimilars and interchangeability: Regulatory, scientific, and global perspectives
10.1016/j.ejps.2025.107224 · 2025 · External reference
Current perspectives on biosimilars
10.1007/s10295-019-02216-z · 2019 · External reference
Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: A systematic literature review
10.1016/j.ejps.2020.105501 · 2020 · External reference
Guidelines on Similar Biologics: Regulatory Requirements for Marketing Authorization in India
2025 · External reference
Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world’s first biosimilar ranibizumab
10.4103/ijo.ijo_2516_20 · 2021 · External reference
Ranizurel safety evaluation in real-world -(RaSER) study
10.1016/j.ajoc.2022.101358 · 2022 · External reference
Biosimilar ranibizumab (ranieyes) safety and efficacy in the real world: BRESER study
10.1177/24741264251322213 · 2025 · External reference
Real-world use of off-label MVASI in the treatment of patients with neovascular AMD and DME
10.1167/tvst.13.7.17 · 2024 · External reference
Aflibercept biosimilar MYL-1701P vs reference aflibercept in diabetic macular edema: The INSIGHT randomized clinical trial
10.1001/jamaophthalmol.2024.3458 · 2024 · External reference
Efficacy, safety, and cost-effectiveness of biosimilars of bevacizumab in näive patients with diabetic macular edema
10.4103/ijp.ijp_58_24 · 2024 · External reference
Biosimilar ranibizumab and innovator ranibizumab—immunogenicity assessment and its impact on safety and efficacy
10.1001/jamaophthalmol.2022.5543 · 2023 · External reference
A multicenter, retrospective study (RE-ENACT 2) on the use of RazumabTM (World’s first biosimilar ranibizumab) in Wet AMD, DME, RVO and Myopic CNV
2019 · External reference
Long-term efficacy and safety of RazumabTM (biosimilar ranibizumab) in Indian patients with retinal diseases: Results from retrospective REAR RD-2 study
10.18203/2349-3259.ijct20222610 · 2022 · External reference
Transitioning from aflibercept to biosimilar ranibizumab in diabetic macular edema (DME): (The TRANSFORM-DME Trial) a multicenter observational study
10.2147/opth.s500912 · 2024 · External reference
Biosimilar candidate CT-P42 in diabetic macular edema
10.1016/j.oret.2024.06.013 · 2024 · External reference
Utility of real-world evidence in biosimilar development
10.1080/10543406.2024.2330217 · 2024 · External reference
Comparison of innovator vs. biosimilar ranibizumab in treating diabetic macular edema: A multicenter retrospective study
10.1007/s40123-022-00463-5 · 2022 · External reference
Biosimilar to biosimilar anti-VEGF switching for retinal diseases
10.1177/24741264231202080 · 2023 · External reference
Intravitreal Stivant® (a biosimilar to bevacizumab) alone versus combined with triamcinolone in center-involved diabetic macular edema
10.1016/j.jfop.2025.100173 · 2025 · External reference
A retrospective, non-randomized, clinical review on the effect of single-dose biosimilar Razumab injection in diabetic macular edema
10.52756/ijerr.2023.v32.010 · 2023 · External reference
Impact of out‐of‐pocket costs on patient initiation, adherence and persistence rates for patients treated with anti‐vascular endothelial growth factor medicines
10.1111/ceo.13706 · 2020 · External reference
Anti–vascular endothelial growth factor biosimilars in ophthalmology
10.1097/iae.0000000000003626 · 2022 · External reference
Ranibizumab biosimilars in treating retinal disorders: A cost-effective revolution?
10.2147/dddt.s457303 · 2024 · External reference
Significant reduction in the cost of care for retinal diseases in India due to the approval of biosimilars: Lessons for health systems
10.25259/ihopejo_1_2024 · 2024 · External reference
The biosimilar paradox
10.1016/j.ophtha.2023.04.019 · 2023 · External reference
The biosimilar paradox: How anti-VEGF biosimilars will increase patient and overall healthcare costs (Ophthalmology. 2023;130:966-973)
10.1016/j.ophtha.2023.07.019 · 2023 · External reference
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER – survey)
10.1080/14712598.2023.2176218 · 2023 · External reference
Need of education on biosimilars amongst ophthalmologists: Combating the nocebo effect
10.1038/s41433-019-0722-6 · 2020 · External reference
Treatment landscape of macular disorders in indian patients with the advent of RazumabTM (World’s first biosimilar ranibizumab): A comprehensive review
10.1007/s40123-021-00362-1 · 2021 · External reference
Mitigating the nocebo effect in biosimilar use and switching: A systematic review
10.1007/s40290-024-00541-y · 2024 · External reference
Emerging biosimilars for retinal diseases
10.1080/17469899.2022.2152005 · 2022 · External reference
An introduction to biosimilars for the treatment of retinal diseases: A narrative review
10.1007/s40123-022-00488-w · 2022 · External reference
